Validation and clinical application of MammaPrint® in patients with breast cancer;Validez clínica y analítica de MammaPrint® en tratamiento del cáncer de mama

Medicina Clinica

Volumn 136, Issue 14, 2011, Pages 627-632

  Cuadros, Marta ^a,b   Llanos, Aurora ^a  

^a Andalusian Agency for Health Technology Assessment Spain   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Breast neoplasm; Gene expression profiling; MammaPrint ; Oligonucleotide array sequence analysis

Indexed keywords

ANALYZER; BREAST CANCER; BREAST CARCINOMA; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SCREENING; COCHRANE LIBRARY; HUMAN; MEDLINE; METASTASIS; OUTCOME ASSESSMENT; REPRODUCIBILITY; REVIEW; VALIDITY;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RISK ASSESSMENT;

EID: 79955974327     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2010.02.009     Document Type: Review

References (20)

1. Asociación española contra el cáncer (AECC) [consultado 22/1/2008]. Disponible en: http://www.muchoxvivir.org/index.jsp? seccion=34.
2. Ferrerincode [consultado 22/1/2008]. Disponible en: http://www. ferrerincode. com/profesionales-productos-MammaPrint®-quees.asp
3. Bueno-de-Mesquita JM, Van Harten WH, Retel VP, Van't Veer LJ, Van Dam FS, Karsenberg K, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER). Lancet Oncol. 2007;8:1079-87.
4. Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, Van Krimpen C, et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat. 2008.
5. Buyse M, Loi S, Van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183-92. (Pubitemid 44390989)
6. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006;7:278.
7. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2008.
8. Van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009. (Pubitemid 35461656)
9. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008;14:2988-93.
10. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, et al. Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008;148:358-69. (Pubitemid 351665467)
11. MammaPrint prognostic test for breast cancer. National Horizon Scanning Centre. Instituto Nacional para la Investigación en Salud (Reino Unido) [consultado 22/1/2009]. Disponible en: http://www.pcpoh.bham.ac.uk/ publichealth/horizon/outputs/documents/2007/september/Mammaprint.pdf
12. ECRI Institute. Emerging technology evidence report. Gene expression profiling of breast cancer to predict the likelihood of recurrence [consultado 22/1/ 2009]. Disponible en: http://www.ta.ecri.org/Topics/prod/home/detail.aspx? d=8769&s=4&p=4
13. Van't Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-6.
14. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA. 2001;98:11462-7. (Pubitemid 32928751)
15. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74. (Pubitemid 32878711)
16. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol. 2009;17:1-7.
17. Espejel F, Roa JC. Surface enhanced laser desorption/ionization (SELDI): tecnología proteómica y su aplicación en oncología. Med Clin (Barc). 2008;131:312-7.
18. Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM. Gene expression assays: New tools to individualize treatment of early-stage breast cancer. Am J Health Syst Pharm. 2008;65:23-8.
19. Gisbert JP, Bonfill X. ¿Cómo realizar, evaluar y utilizar revisiones sistemáticas y metaanálisis? Gastroenterol Hepatol. 2004;129-49.
20. MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy). European Organisation for Research and Treatment of Cancer (EORTC) [consultado 28/10/2008]. Disponible en: http://www.breastinternationalgroup.org/ downloads/latestnews/27-07-05/MINDACT-trial-overview